查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1481293

骨髓增生性疾病藥物/治療市場規模 - 依疾病類型（Ph+ CML、Ph- MPN [真性紅血球增多症、原發性血小板增多症、骨髓纖維化]）、藥物類別（酪胺酸激酶、JAK）、給藥途徑、最終用途和預測，2024 年 - 2032

Myeloproliferative Disorders Drugs/Treatment Market Size - By Disorder Type (Ph+ CML, Ph- MPN [Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis]), Drug Class (Tyrosine Kinase, JAK), Route of Administration, End-use & Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於真性紅血球增多症、原發性血小板增多症和骨髓纖維化等骨髓增生性疾病的盛行率不斷增加，骨髓增生性疾病藥物/治療市場預計 2024 年至 2032 年複合年成長率為 3.2%。根據 AACR（美國癌症研究協會）的數據，美國估計有 13,000 人患有骨髓纖維化。因此，對有效藥物和治療方法來控制症狀、改善生活品質和延長患者生存期的需求不斷成長。此外，醫學研究和藥物開發的進步導致針對骨髓增殖性疾病特定分子途徑的新療法的發現。

隨著全球人口老化，這些疾病的盛行率預計將上升，進一步推動對藥物和治療的需求。此外，醫療保健專業人員和患者對早期診斷和及時干預的意識正在增強。對及時診斷的高度重視，因為它允許啟動適當的治療來幫助管理症狀、預防疾病進展和改善患者的治療結果，這將有利於市場的成長。

骨髓增生性疾病藥物/治療產業分為疾病類型、藥物類別、給藥途徑、最終用途和地區。

根據給藥途徑，口腔領域的市場價值預計在2024 年至2032 年期間以3.1% 的複合年成長率成長，因為它們為患者提供了便利和靈活性，使他們能夠在家中進行治療，而無需頻繁去診所就診。這增強了患者的便利性，從而提高了治療依從性並提高了生活品質。此外，藥物研究的進步導致針對骨髓增生性疾病特定分子途徑的口服藥物的開發，以提供更有效和有針對性的治療選擇。

就最終用途而言，到2032 年，專科診所領域的骨髓增殖性疾病藥物/治療市場將實現3.3% 的成長率。護理所推動的。這些診所提供量身定做的治療計劃、密切監測和先進療法，以確保疾病的最佳管理。此外，專科診所通常充當轉診中心，吸引來自廣泛地理區域尋求專業護理的患者。此外，專科診所和製藥公司之間為促進臨床試驗和創新療法開發而進行的合作正在進一步推動市場成長。

由於醫學研究和藥物開發的進步，歐洲骨髓增生性疾病藥物治療市場規模到 2032 年可能會以 3.3% 的複合年成長率大幅擴張，特別是在德國和英國等擁有健全醫療保健系統的國家。專注於血液疾病的學術中心將促進臨床醫生和研究人員之間的合作，從而開發客製化療法。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 全球骨髓增生性疾病發生率不斷上升
      • 加大新藥研發力度
      • 標靶治療不斷進步
      • 老年人口增加
    • 產業陷阱與挑戰
      • 治療選擇有限
      • 治療費用高
      • 與藥物相關的不良反應
  • 成長潛力分析
  • 管道分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 主要市場參與者的競爭分析，
  • 競爭定位矩陣
  • 戰略儀錶板

第 5 章：市場估計與預測：按疾病類型，2018-2032

  • 主要趨勢
  • 費城染色體陽性 (Ph+) CML
  • 費城染色體陰性 (Ph-) MPN
    • 真性紅血球增多症
    • 原發性血小板增多症
    • 骨髓纖維化
  • 其他疾病類型

第 6 章：市場估計與預測：按藥物類別，2018-2032 年

  • 主要趨勢
  • 酪胺酸激酶抑制劑
  • Janus激酶抑制劑
  • 羥基脲
  • 其他藥物類別

第 7 章：市場估計與預測：按管理途徑，2018-2032 年

  • 主要趨勢
  • 口服
  • 可注射

第 8 章：市場估計與預測：按最終用途，2018-2032 年

  • 主要趨勢
  • 醫院
  • 專科診所
  • 其他最終用戶

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

  • 主要動向：按地區
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 中東和非洲其他地區

第 10 章：公司簡介

  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc (GSK)
  • GL Pharma GmbH
  • Incyte Corporation
  • Janssen Biotech, Inc. (Johnson & Johnson)
  • MorphoSys AG
  • Mylan N.V. (Viatris)
  • Novartis Pharmaceuticals Corporation (Novartis AG)
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
簡介目錄
Product Code: 8372

Myeloproliferative disorders drugs/treatment market is estimated to register 3.2% CAGR between 2024 and 2032, owing to the increasing prevalence of myeloproliferative disorders, such as polycythemia vera, essential thrombocythemia, and myelofibrosis. As per AACR (American Association for Cancer Research), an estimated 13,000 people were living with myelofibrosis in the U.S. These disorders are characterized by the abnormal production of blood cells in the bone marrow, leading to various complications. Consequently, there is a growing demand for effective drugs and treatments to manage symptoms, improve quality of life, and prolong survival among patients. Additionally, advancements in medical research and drug development have led to the discovery of novel therapies targeting specific molecular pathways involved in myeloproliferative disorders.

With aging population worldwide, the prevalence of these conditions is expected to rise, further driving the demand for drugs and treatments. Moreover, the awareness among healthcare professionals and patients about early diagnosis and prompt intervention is increasing. The strong focus on timely diagnosis as it allows the initiation of appropriate treatments to help manage symptoms, prevent disease progression, and improve patient outcomes will favor the market growth.

The myeloproliferative disorders drugs/treatment industry is classified into disorder type, drug class, route of administration, end-use and region.

Based on route of administration, the market value from the oral segment is slated to grow at 3.1% CAGR during 2024-2032, as they offer convenience and flexibility for patients, allowing them to administer treatments at home without the need for frequent clinic visits. This enhanced patient convenience leads to better treatment adherence and improved quality of life. Additionally, advancements in pharmaceutical research have resulted in the development of oral drugs targeting specific molecular pathways involved in myeloproliferative disorders for offering more effective and targeted treatment options.

In terms of end-use, the myeloproliferative disorders drugs/treatment market from the specialty clinics segment will record 3.3% growth rate through 2032. This is driven by their specialized expertise and comprehensive care in managing complex hematologic conditions like myeloproliferative disorders. These clinics provide tailored treatment plans, close monitoring, and access to advanced therapies for ensuring optimal management of the disease. Additionally, specialty clinics often serve as referral centers, attracting patients seeking specialized care from a wide geographic area. Moreover, collaborations between specialty clinics and pharmaceutical companies for facilitating clinical trials and the development of innovative therapies are further driving the market growth.

Europe myeloproliferative disorders drug treatment market size may expand substantially at 3.3% CAGR up to 2032, attributed to the advancements in medical research and drug development, particularly in countries with robust healthcare systems like Germany and the U.K. Furthermore, the presence of specialized healthcare facilities and academic centers focusing on hematologic diseases in Europe will foster collaboration between clinicians and researchers, leading to the development of tailored therapies.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Forecast parameters
  • 1.4 Data collection
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence of myeloproliferative diseases globally
      • 3.2.1.2 Increasing R&D efforts to develop new drugs
      • 3.2.1.3 Growing advancement in targeted therapies
      • 3.2.1.4 Increasing geriatric population
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Limited treatment options
      • 3.2.2.2 High cost of treatment
      • 3.2.2.3 Adverse effects associated with the drugs
  • 3.3 Growth potential analysis
  • 3.4 Pipeline analysis
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players,
  • 4.4 Competitive positioning matrix
  • 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Disorder Type, 2018-2032 ($ Million)

  • 5.1 Key trends
  • 5.2 Philadelphia chromosome-positive (Ph+) CML
  • 5.3 Philadelphia chromosome-negative (Ph-) MPNs
    • 5.3.1 Polycythemia vera
    • 5.3.2 Essential thrombocythemia
    • 5.3.3 Myelofibrosis
  • 5.4 Other disorder types

Chapter 6 Market Estimates and Forecast, By Drug Class, 2018-2032 ($ Million)

  • 6.1 Key trends
  • 6.2 Tyrosine kinase inhibitors
  • 6.3 Janus kinase inhibitors
  • 6.4 Hydroxyurea
  • 6.5 Other drug classes

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018-2032 ($ Million)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Injectable

Chapter 8 Market Estimates and Forecast, By End-Use, 2018-2032 ($ Million)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Specialty clinics
  • 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

  • 9.1 Key trends, by region
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 AbbVie Inc.
  • 10.2 Bristol-Myers Squibb Company
  • 10.3 Eli Lilly and Company
  • 10.4 GlaxoSmithKline plc (GSK)
  • 10.5 GL Pharma GmbH
  • 10.6 Incyte Corporation
  • 10.7 Janssen Biotech, Inc. (Johnson & Johnson)
  • 10.8 MorphoSys AG
  • 10.9 Mylan N.V. (Viatris)
  • 10.10 Novartis Pharmaceuticals Corporation (Novartis AG)
  • 10.11 Takeda Pharmaceutical Company Limited
  • 10.12 Teva Pharmaceutical Industries Ltd.